Towa Pharmaceutical Co., Ltd.
Stock Price Chart
2026/07/10 UpdatedPrice Trend
2026/07/10 UpdatedPrice & Trading Details
2026/07/10 UpdatedPRICE
TRADING
Analyst Recommendations 5 analysts
Updated 2026/07/01Earnings Calendar
Updated 2026/07/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/05/13 | ¥107.04 | ¥-240.35 | -324.5% |
| 2026/02/12 | ¥73.56 | ¥180.15 | +144.9% |
| 2025/11/10 | ¥62.02 | ¥115.80 | +86.7% |
| 2025/08/06 | ¥63.46 | ¥51.06 | -19.5% |
Shareholder Composition
Updated 2026/07/01Major Holders
Updated 2026/07/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Brown Capital Mgmt Mutual Fd.s-Brown Capital Mgmt Intl Small Company F
|
1.9M | -19.98% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
355.2K | 0.00% | |
|
American Century ETF Trust-Avantis International Small Cap Value ETF
|
313.4K | -1.23% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
231.9K | +2.84% | |
|
DFA INVESTMENT TRUST CO-The Japanese Small Company Series
|
161.6K | 0.00% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-DFA Intl Small Cap Value PORT.
|
154.3K | 0.00% |
Dividend History
Updated 2026/07/05| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥40 | -50.0% |
| 2025 | ¥80 | +33.3% |
| 2024 | ¥60 | 0.0% |
| 2023 | ¥60 | -4.8% |
| 2022 | ¥63 | - |
Financial Performance
2026/07/05 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥165,615M | ¥208,859M | ¥227,934M | ¥259,594M |
| Gross Profit | ¥70,185M | ¥72,713M | ¥81,383M | ¥94,729M |
| Operating Income | ¥19,205M | ¥5,514M | ¥17,648M | ¥23,243M |
| Pretax Income | ¥22,476M | ¥5,240M | ¥25,406M | ¥27,957M |
| Net Income | ¥15,914M | ¥2,201M | ¥16,173M | ¥18,986M |
| EPS | ¥316.19 | ¥44.72 | ¥328.59 | ¥385.71 |
| Operating Margin | 11.60% | 2.64% | 7.74% | 8.95% |
| Balance Sheet | ||||
| Total Assets | ¥332,097M | ¥371,347M | ¥430,653M | ¥470,823M |
| Total Equity | ¥132,168M | ¥136,893M | ¥155,892M | ¥171,624M |
| Total Liabilities | ¥199,929M | ¥234,454M | ¥274,761M | ¥299,199M |
| Cash | ¥32,830M | ¥24,257M | ¥29,650M | ¥45,471M |
| Interest-bearing Debt | ¥140,701M | ¥161,518M | ¥203,308M | ¥230,983M |
| Equity Ratio | 39.80% | 36.86% | 36.20% | 36.45% |
| D/E Ratio | 1.06 | 1.18 | 1.30 | 1.35 |
| Cash Flow | ||||
| Operating CF | ¥22,129M | ¥2,544M | ¥8,212M | ¥23,401M |
| Investing CF | -¥59,729M | -¥30,284M | -¥40,394M | -¥31,287M |
| Financing CF | ¥46,540M | ¥17,481M | ¥35,407M | ¥21,567M |
| Free CF | ¥8,553M | -¥27,925M | -¥31,113M | -¥7,822M |
| Efficiency | ||||
| ROE | 12.04% | 1.61% | 10.37% | 11.06% |
| ROA | 4.79% | 0.59% | 3.76% | 4.03% |
Latest IR Information
-
Notice of Completion of Payment for Transfer-Restricted Stock as Treasury Stock Acquisition
Disposal of treasury stock completed. Disposed shares: 1,188 common shares; payment per share: 3,835 yen; total payment: 4,555,980 yen. Disposed to three internal directors (excluding outside directors, etc.), payment date: 2026-07-10.
Read more -
Notice of Allotment of Shares in Tanabe Pharma Factory Co., Ltd. (Complete Subsidiary) and Succession of Manufacturing and Marketing Approval
Completely acquired Tanabe Pharma Factory Co., Ltd. as a subsidiary and inherited 17 components and 35 products in its manufacturing and marketing approvals. The acquired shares are 22,602 shares (100%), with transfer planned for late November 2026 and succession of...
Read more -
【Towa Pharmaceutical】Announcement of Executive Changes | June 24, 2026
Towa Pharmaceutical announced the personnel changes at the General Meeting of Shareholders and Board of Directors held on June 24, 2026, revealing new and reappointed directors. President and CEO Ichiro Yoshida will continue in his role, while Koji Nakamura was...
Read more -
Notice of Parent Company's Financial Results | June 24, 2026
Reporting the financial results of the parent company, Yoshida Office Co., Ltd., for the fiscal year ending March 2026. While sales figures are unspecified, net assets are 15,685,795 thousand yen, and net income for the period is 1,762,273 thousand yen....
Read more -
【Towa Pharmaceutical】Share Buyback and Introduction of Director Compensation System | June 2026
Towa Pharmaceutical decided at its Board of Directors meeting on June 24, 2026, to dispose of 1,188 shares of treasury stock in accordance with its director compensation system, with the disposal scheduled for July 10. The purpose is to enhance...
Read more -
[Towa Pharmaceutical] Notice Regarding Controlling Shareholder ｜ June 24, 2026
Towa Pharmaceutical discloses that its parent company, Yoshida Office Co., Ltd., owns 40.85% of voting rights, and CEO Isao Yoshida also serves as a director of the company. The company states that its operational independence is maintained.
Read more
Latest News (5 items)
-
Average Analyst Rating: strong_buy
Average Target Price: ¥5,250
Rating Score: 1.50 (Based on 5 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. It operates through two segments; Domestic and Overseas. The company provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from Tablets, Capsules, Injectable, Patches, eye drops, and other products. It also offers IT service related to healthcare; disease risk testing services; and quasi drugs. In addition, the company is involved in research and development and production of active pharmaceutical ingredients, intermediates, support business; and planning, development and OEM manufacturing of health foods, pharmaceuticals, general foods, and other miscellaneous merchandizes. The company was founded in 1951 and is headquartered in Osaka, Japan.
